FDA Approves Next-Gen Drug for Relapsed CLL After Dana-Farber Study miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
BeiGene s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual
NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.The second-generation Bruton tyrosine kinase (BTK) inhibitor also had a better safety profile than ibrutinib (Imbruvica; Pharmacyclics, Janssen), particularly with